Shanghai MicroPort Endovascular MedTech Co., Ltd Class A
SSSE:68801683.47
CNY
+0.02
(+0.02%)
ISIN
CNE100003MJ5
Return %
Stock
S&P 500
1Y
-19.66
14.20
3Y
-32.91
81.12
5Y
-48.62
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Qing Zhu
- Full Time Employees
- 822
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- No. 1, Lane 3399 Shanghai SH China 201318
- IPO Date
- Jul 22, 2019
- Website
- endovastec.com
- Similar Companies
- Business
- Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec) develops, manufactures, and sells innovative interventional medical devices focused on aortic, peripheral vascular, and tumor treatments. Founded in 2012 and headquartered in Shanghai's International Medical Zone, the company lists on the Shanghai Stock Exchange's STAR Market under ticker 688016.SS and operates a subsidiary of MicroPort Scientific Corp with facilities including nearly 24,000 square meters of R&D, manufacturing, and office space plus Class 10,000 clean rooms. Its core products encompass thoracic and abdominal aortic stent grafts such as Castor Branched Aortic Stent-Graft, Hercules Thoracic Stent Graft (including low-profile variants), Minos Abdominal Aortic Stent-Graft, Talos Thoracic Stent Graft, Cratos Thoracic Branch Stent Graft, and Hector Multi-Branch Thoracic Aortic Stent-Graft; surgical stent grafts like Fontus Branched Surgical Stent Graft; peripheral vascular devices including Reewarm PTX Drug-Coated Balloon Catheter, Hyperflex Balloon Catheter, peripheral vascular stents, and balloon dilatation catheters; and tumor intervention solutions via subsidiary Intervastec; marketed under brands like Endovastec, Castor, Hercules, Minos, Aegis, CRONUS, Fontus, and Talos. Endovastec products serve over 2,400 hospitals across 31 provinces in China—where aortic endovascular intervention holds a 29% domestic market share—and extend to 40 countries and regions in Europe, Latin America, Southeast Asia, and beyond, treating peripheral venous diseases, arterial diseases, aortic conditions, and tumors. The company maintains five subsidiaries—Bluevastec for peripheral venous devices, VasoLutions for peripheral arterial solutions, Intervastec for tumor interventions, Endovastec US in Irvine, California, and Lombard Medical (fully acquired in 2024 including its Aorfix and Altura products)—and invests over 15% of annual revenue in R&D, securing more than 230 patents and eight products under China's innovative medical device green path. Recent developments include the August 2024 completion of acquiring 72.37% equity in Optimum Medical Device Inc., integrating Lombard Medical as a wholly-owned subsidiary to bolster European operations; EU Custom-Made Device certification for Cratos Thoracic Branch Stent Graft in August 2024; first pre-market implantations of Cratos in Switzerland and Hector in Europe during early 2024; 12 new product approvals in China and international markets through 2024-2025; and market entries or approvals in Singapore, Thailand, Azerbaijan, Brazil, and Colombia for products like Castor, Hercules-LP, Minos, and Reewarm PTX.